阿托伐他汀钙片治疗脑卒中并脑微出血的临床研究

Clinical Study of Atorvastatin Calcium Tablets in the Treatment of Stroke and Cerebral Microhemorrhage

目的探讨阿托伐他汀钙片治疗脑卒中并脑微出血的疗效及安全性。方法选取我院2016年1月~2018年1月收治的112例脑卒中并脑微出血患者为观察对象,按照随机数表法分为对照组和研究组,每组56例。两组均给予常规治疗,研究组加用阿托伐他汀钙片治疗,比较两组疗效、不良反应、出血病灶数量。结果研究组总有效率高于对照组(92.86%vs75.00%),差异有统计学意义(P<0.05);治疗后两组出血病灶数量均减少,其中研究组治疗后出血病灶为(2.16±1.74)个,少于对照组的(4.23±1.98)个,差异有统计学意义(P<0.05);研究组不良反应率高于对照组(14.29%vs10.71%),但差异无统计学意义(P>0.05)。结论阿托伐他汀钙片可减少脑卒中并脑微出血患者的出血病灶,提高临床疗效,且不会增加不良反应。

Objective To investigate the efficacy and safety of atorvastatin calcium tablets in stroke and cerebral microhemorrhage. Methods A total of 112 patients with stroke and cerebral microhemorrhage admitted to our hospital from January 2016 to January 2018 were enrolled in the study. They were divided into control group and study group according to the random number table method, with 56 cases in each group. Routine treatment was given to both groups, and the study group was treated with atorvastatin calcium tablets. The efficacy, adverse reactions, and number of bleeding lesions were compared between the two groups.Results The total effective rate of the study group was higher than that of the control group (92.86% vs 75.00%), the difference was statistically significant (P<0.05). The number of hemorrhagic lesions decreased after treatment, and the hemorrhagic lesions in the study group were (2.16±1.74), less than the control group (4.23±1.98), the difference was statistically significant (P<0.05);the adverse reaction rate of the study group was compared with the control group (14.29% vs 10.71%), the difference was not statistically significant (P>0.05).Conclusion Atorvastatin calcium tablets can significantly reduce the bleeding of patients with stroke and cerebral microhemorrhage, improve clinical efficacy, and will not increase adverse reactions.